![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset uncommon and orphan illness biopharmaceutical firm creating medical stage applications based mostly on epidermal development components and a differentiated, proprietary xB3 ™ platform for delivering therapeutics throughout the blood-brain barrier (“BBB”) and the remedy of central nervous system (“CNS”) issues in areas of excessive unmet medical want, at present introduced it has filed its unaudited quarterly monetary statements and administration’s dialogue and evaluation for the interval ended August 31, 2022. All can be found beneath the Company’s profile on SEDAR at www.sedar.com and on the Company’s web site at www.bioasis.us.
On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Executive Chair of the Board
Follow on:
Facebook
Instagram
LinkedIn
Twitter
BTI-FIN
About Bioasis
Bioasis Technologies Inc. is a multi-asset uncommon and orphan illness biopharmaceutical firm creating medical stage applications based mostly on epidermal development components and the xB3 ™ platform, a proprietary expertise for the supply of therapeutics throughout the blood mind barrier and the remedy of CNS issues in areas of excessive unmet medical want. The supply of therapeutics throughout the blood-brain barrier represents the ultimate frontier in treating neurological issues. The in-house improvement applications at Bioasis are designed to develop symptomatic and disease-modifying remedies for brain-related ailments and issues. For extra details about the Company, please go to www.bioasis.us.
Forward Looking Statements
Certain statements on this press launch comprise forward-looking statements inside the that means of the Private Securities Litigation Reform Act of 1995 or forward-looking data beneath relevant Canadian securities laws that is probably not based mostly on historic reality together with different statements containing the phrases “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and comparable expressions. Such forward-looking statements or data contain recognized and unknown dangers, uncertainties and different components which will trigger our precise outcomes, occasions or developments, or trade outcomes, to be materially completely different from any future outcomes, occasions or developments categorical or implied by such forward-looking statements or data. Such components embody, amongst others, our stage of improvement, lack of any product revenues, extra capital necessities, threat related to the completion of medical trials and acquiring regulatory approval to market our merchandise, the power to guard our mental property, dependence on collaborative companions and the prospects for negotiating extra company collaborations or licensing preparations and their timing. Specifically, sure dangers and uncertainties that might trigger such precise occasions or outcomes expressed or implied by such forward-looking statements and data to vary materially from any future occasions or outcomes expressed or implied by such statements and data embody, however aren’t restricted to, the dangers and uncertainties that: merchandise that we develop might not reach preclinical or medical trials, or future merchandise in our focused company aims; our future working outcomes are unsure and prone to fluctuate; we might not be capable to elevate extra capital; we is probably not profitable in establishing extra company collaborations or licensing preparations; we might not be capable to set up advertising and marketing and the prices of launching our merchandise could also be better than anticipated; we’ve got no expertise in industrial manufacturing; we might face unknown dangers associated to mental property issues; we face elevated competitors from pharmaceutical and biotechnology corporations; and different components as described intimately in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these dangers and uncertainties, you might be cautioned to not place undue reliance on such forward-looking statements and data, that are certified of their entirety by this cautionary assertion. All forward-looking statements and data made herein are based mostly on our present expectations and we undertake no obligation to revise or replace such forward-looking statements and data to replicate subsequent occasions or circumstances, besides as required by legislation.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that time period is outlined within the insurance policies of the TSX Venture Exchange) accepts duty for the adequacy or accuracy of this launch
Contacts:
Deborah Rathjen, Ph.D., Executive Chair of the Board and CEO
[email protected]
203-533-7082
Investor Contact:
Graeme Dick
Colwell Capital Corp.
[email protected]
403-561-8989
